Health Tips
Understanding Opioid Receptors: How They Shape Pain Relief and Side Effects
Most of us learned a tidy picture in school: a drug is a key, a receptor is a lock, and when the right key turns, something happens. That picture is a decent start, but opioid receptors behave less like a single lock and more like a dimmer switch wired into many rooms of a house. Turn the dial up, and the lights change everywhere the wiring runs, not just in the room you meant to brighten.
Those rooms include the brain, the spinal cord, the gut, and the control centre in the brainstem that sets your breathing rhythm. So when a medicine such as oxycodone turns the dial to ease pain, it also dims the bowel, slows breathing a little, shrinks the pupils and can lift mood. None of that is random. Each effect traces back to where the switches are installed and how strongly the drug presses them.
Understanding opioid receptors helps make sense of questions patients ask all the time. Why does constipation hang around when drowsiness fades? How can a nasal spray reverse an overdose in minutes? Why does one person do well on a medicine that barely helps someone else? This guide walks through the receptor family as a whole, using oxycodone as the running example, in plain language you can bring to your next conversation with a prescriber or pharmacist.
Key terms in 60 seconds
Skim these terms once, and the rest of the article will read more easily.
| Term | Plain meaning |
|---|---|
| Receptor | A protein on or in a cell that waits for a specific chemical signal and then changes what the cell does. |
| Ligand | Any molecule that attaches to a receptor. |
| Agonist | A ligand that attaches and switches the receptor on. |
| Partial agonist | A ligand that switches the receptor on, but only part of the way, even when every receptor is occupied. |
| Antagonist | A ligand that sits in the receptor without switching it on, blocking other molecules from getting in. |
| Affinity | How tightly a molecule clings to the receptor. High affinity means it grabs on and is hard to push off. |
| Efficacy | How strong a response the molecule produces once attached. Affinity is about grip; efficacy is about effect. |
| G protein–coupled receptor | A large receptor family that passes its message inward through a helper called a G protein. All opioid receptors belong here. |
| Endogenous opioid | A painkilling chemical your own body makes, such as an endorphin. |
| Tolerance | Needing more of a drug to get the same effect, because the body has adjusted to it. |
A drug can hold on very tightly yet produce only a modest effect, which explains several medicines further down.
Meet the opioid receptor family
Scientists recognise four members of this family. The international pharmacology naming body, IUPHAR, gives them short codes: MOP (mu), DOP (delta), KOP (kappa) and NOP (the nociceptin receptor, sometimes called ORL1). A fifth candidate, the sigma receptor, was once grouped with them but has since been dropped, partly because naloxone does not reverse its effects. All four are G protein–coupled receptors, each with its own natural partners and pattern of effects. A detailed review table of opioid receptor functions lays out these roles for readers who want the technical version.
Mu (MOP): the main target for pain medicines
| Natural partner | Beta-endorphin, endomorphins, and to a lesser degree enkephalins |
| Main locations | Pain-processing areas of the brain, the spinal cord, the brain stem, reward circuits, the gut wall |
| Effects when switched on | Pain relief, slowed breathing, sedation, euphoria, slowed bowel, urinary retention, itch, tolerance and dependence over time |
| Medicines that act here | Oxycodone, morphine, hydromorphone, fentanyl, codeine (via morphine), buprenorphine (partially), naloxone and naltrexone (as blockers) |
The mu opioid receptor is the workhorse. Almost every opioid prescribed for pain, oxycodone included, does most of its work here, which is why the benefits and the risks of these drugs overlap so heavily. Medicines differ in binding and speed, as you can see when comparing oxycodone and morphine side by side, but the receptor they share is the same. That shared target is also why a single blocker, naloxone, can reverse an overdose from many different opioids.
Delta (DOP): the quieter cousin
| Natural partner | Enkephalins |
| Main locations | Brain regions tied to mood and emotion, the spinal cord, peripheral nerves, the gut |
| Effects when switched on | Pain relief (with less effect on breathing in research studies), roles in mood and anxiety |
| Medicines that act here | No approved medicines target delta selectively; it remains mainly a research focus |
In laboratory studies, switching delta receptors on eased some kinds of pain while touching breathing less than mu activation does. That promise has not yet become a prescription painkiller, so delta is something researchers discuss more than patients encounter.
Kappa (KOP): relief with a darker edge
| Natural partner | Dynorphins |
| Main locations | Spinal cord, brain areas involved in stress and mood, peripheral nerves |
| Effects when switched on | Pain relief, pupil constriction, sedation, increased urine output, and dysphoria (an uneasy, low or unsettled mood) |
| Medicines that act here | Mixed agonist–antagonists such as butorphanol and nalbuphine |
Kappa and delta receptors are often grouped together as the “other” opioid receptors, but they behave very differently. The Kappa activation can ease pain, yet instead of a pleasant lift it tends to bring an unpleasant, uneasy feeling. That dysphoria partly explains why kappa-heavy drugs never replaced mu-based painkillers.
Nociceptin (NOP): the odd one out
| Natural partner | Nociceptin (also called orphanin FQ) |
| Main locations | Brain and spinal cord, widely spread |
| Effects when switched on | Pain relief at the spinal level, roles in tolerance, stress and feeding; effects in the brain can be complex |
| Medicines that act here | None approved that target it selectively; studied as a research target |
The nociceptin receptor looks like a member of the family on paper, yet classic opioid drugs barely touch it, and naloxone does not block it well. Researchers are curious about its role in tolerance, but it plays little direct part in how oxycodone works today.
Your body’s own opioids
It can seem strange that the human body comes fitted with receptors for chemicals found in the poppy plant. The answer is that the plant chemicals happen to mimic messengers we already make. Our own opioids, called endogenous opioids, are small protein fragments released by nerve cells and glands. They turn down pain signals and help shape stress responses and reward.
| Endogenous opioid | Main receptor | When the body releases it |
|---|---|---|
| Beta-endorphin | Mu | Physical stress, injury, sustained exercise, and possibly during laughter and social bonding (evidence for these last two is more modest) |
| Enkephalins | Delta and mu | Locally in the spinal cord and brain when pain signals arrive; also in the gut and adrenal glands during stress |
| Dynorphins | Kappa | Prolonged stress and ongoing pain; linked with low or uneasy mood |
| Endomorphins | Mu | Pain-processing areas of the brain and spinal cord; their exact roles are still being studied |
| Nociceptin | NOP | Widely in the brain and spinal cord, with roles in stress, feeding and pain modulation |
Why have this system at all? A useful way to picture it: pain is an alarm, and the body needs a way to turn the alarm down when shouting it louder would not help. Someone escaping danger on an injured ankle benefits from feeling less pain for a while; later the pain returns, nudging rest and healing. The same wiring links pain relief with reward, which helps explain why opioid medicines can affect mood and motivation. Our piece on how oxycodone affects mood, anxiety and emotional well-being looks at that side in more depth.
Your own opioids are released in small, local, short-lived bursts. A tablet reaches the whole body for hours, which is one reason medicines cause effects, like heavy constipation, that the natural system rarely does.
Why receptor location explains side effects
Back to the dimmer switch. A pill cannot choose which rooms it lights up. Once oxycodone is in the bloodstream, it reaches mu receptors wherever they sit, so the drug’s effects form a kind of map of where those receptors live. Where are opioid receptors located? The table below follows them around the body.
| Location | Receptor effect | What you notice |
|---|---|---|
| Spinal cord (dorsal horn) | Fewer pain messages passed up toward the brain | Pain relief |
| Brain pain-processing areas | Pain signals feel less intense and less distressing | Pain still present but “bothers you less” |
| Brain stem breathing centre | Less sensitive to rising carbon dioxide | Slower, shallower breathing; dangerous at high levels |
| Gut wall | Slower muscle movement, less fluid secretion | Constipation, bloating |
| Nerves controlling the pupils | Pupil-constricting signal increased | Pinpoint pupils |
| Brain reward areas | Dopamine-linked reward signals boosted | Euphoria or calm; risk of misuse |
| Vomiting trigger zone | Nausea signals activated | Queasiness, vomiting, especially early on |
| Skin and itch pathways | Itch signals altered; some opioids also release histamine | Itching, sometimes without any rash |
| Bladder | Weaker emptying signal, tighter outlet | Trouble starting to urinate, retention |
| Brain arousal and sleep systems | Alertness reduced, sleep stages altered | Drowsiness; lighter or disturbed sleep |
Each row has its own story. Pupils shrink because mu activation boosts a nerve signal that tightens the iris, as explained in our article on why oxycodone makes your pupils small. Nausea comes from the vomiting trigger zone near the brain stem plus changes in the gut and inner ear, covered in why you might feel nauseous after taking oxycodone. Itching has a few causes at once, which our guide on itching without a rash on oxycodone unpacks. Sleep effects get their own deep look at how oxycodone affects your rest.
One pattern stands out. As the body adjusts over days to weeks, several effects such as drowsiness and nausea often ease. Constipation and pinpoint pupils, by contrast, tend to change very little with tolerance. The gut simply does not adapt the way brain circuits do. That is why many prescribers suggest a bowel plan from the first day. Our article on why oxycodone causes constipation and how to manage it covers practical steps.
Breathing deserves the most respect. Slowed breathing is most likely during the opening two or three days on an opioid and right after a dose goes up, and it rises sharply when opioids are combined with alcohol, benzodiazepines or other sedating medicines. The MedlinePlus oxycodone information page lists these warnings in patient-friendly language.
From full agonist to blocker: the opioid receptor spectrum
Rather than sorting opioid medicines into “strong” and “weak,” it helps to line them up by what they do at the receptor. Picture a dial running from fully on to firmly blocked. Agonist vs antagonist vs partial agonist is really a question of where on that dial a drug sits.
- Full agonists. Oxycodone, morphine, hydromorphone and fentanyl can switch mu receptors fully on. More drug means more effect, both for pain relief and for breathing suppression, with no built-in ceiling. They differ in potency and speed; see how oxycodone compares with fentanyl for one striking example.
- Partial agonist. Buprenorphine binds mu receptors very tightly (high affinity) but turns them only part of the way on (lower efficacy). Its effect on breathing tends to level off at higher doses, a so-called ceiling effect, which gives it a wider safety margin, though not a perfect one, especially when mixed with other sedatives. Because it grips so hard, it can push full agonists off the receptor and trigger sudden withdrawal if started at the wrong time.
- Mixed agonist–antagonists. Drugs such as butorphanol and nalbuphine switch kappa receptors on while acting only weakly at mu, or even blocking it. They can ease pain, but they can also cause dysphoria and weaken full agonists given alongside them.
- Antagonists. Naloxone, nalmefene and naltrexone sit in mu receptors without switching them on. Naloxone and nalmefene are rescue medicines for overdose. Naltrexone lasts much longer and is used in treatment programmes for opioid and alcohol use disorders to block opioid effects over time.
- Peripherally acting antagonists. Methylnaltrexone and naloxegol were designed to stay mostly outside the brain. They block mu receptors in the gut, easing opioid-induced constipation, while leaving pain relief in the brain and spinal cord largely intact.
How naloxone works
Naloxone has a higher grip on mu receptors than most opioids, so when it arrives in large amounts, it elbows them out of the way and takes their seats, without switching anything on. Within minutes, dangerously slow breathing can pick back up. In someone who is physically dependent, this also triggers withdrawal, which is unpleasant but far less dangerous than an overdose.
The catch is timing. Naloxone is cleared from the body relatively quickly, and many opioids, especially long-acting tablets and some potent synthetic drugs, stay around longer. When the naloxone fades, the remaining opioid can reclaim the receptors and breathing can slow again. That is why 911 should always be called, even if the person wakes up. Naloxone nasal spray has been available over the counter in the US since March 2023, and a nalmefene nasal spray was approved in May 2023 as a prescription product. The FDA’s page on naloxone and nalmefene explains the available forms.
What happens inside a nerve cell
So far we have looked at the receptor from the outside. Here is the sequence that follows once oxycodone settles into a mu receptor on a pain-carrying nerve cell.
- Binding. The drug fits into a pocket on the outside of the receptor. This changes the receptor’s shape.
- G protein switches on. On the inside of the cell, the reshaped receptor activates an attached helper protein from the inhibitory “Gi/o” group.
- Less cAMP. One piece slows an enzyme that makes cyclic AMP (cAMP), a messenger molecule that generally keeps nerve cells revved up. Less cAMP means a quieter cell.
- Potassium channels open. Another piece opens potassium channels, letting positive charge leak out. The cell becomes more electrically negative (hyperpolarised), so it is harder to fire.
- Calcium channels close. At the nerve ending, calcium normally rushes in to trigger the release of chemical messengers. With calcium channels partly shut, less of that trigger arrives.
- Less pain-signal chemical released. The end result is fewer chemical messengers, such as glutamate and substance P, crossing to the next nerve. The pain message reaching the brain is smaller and weaker.
The same chain of events plays out in the breathing centre, the gut and elsewhere. That is the root of the side-effect map above: the cell machinery is shared, so quieting nerves in one place means quieting them in others too.
How opioid receptors adapt over time
When receptors are switched on day after day, the cell adjusts to bring itself back toward balance. These changes are normal biology, not a sign of weakness or misuse.
Desensitization
Within minutes to hours of steady activation, enzymes tag the receptor with phosphate groups. A protein called beta-arrestin then binds the tagged receptor and partly uncouples it from its G protein. The receptor is still on the cell surface but responds more feebly, like a doorbell whose wire has been loosened.
Internalization
Beta-arrestin can also guide receptors off the surface and into the cell, where they are either recycled back out or broken down. Fewer receptors on the surface means fewer switches for the drug to press.
Tolerance
Over days to weeks, these receptor changes add up with wider shifts in the nervous system. The same dose gives less effect, so tolerance develops. It does not build evenly: tolerance to drowsiness and nausea often comes fairly quickly, tolerance to pain relief varies, and tolerance to constipation and pupil narrowing is limited. Tolerance to breathing effects does develop, but it fades fast during a pause, so going straight back to a former dose after time away carries real overdose risk. Our article on oxycodone tolerance and what to do about it covers the practical side.
Physical dependence
To stay balanced while receptors are constantly dimmed, the cell turns up its own internal machinery, for instance by making more cAMP. If the opioid is then stopped suddenly, that over-revved machinery is suddenly unopposed. The result is withdrawal: aches, sweating, diarrhoea, yawning, restlessness and anxiety. Physical dependence is expected with regular use and is not the same thing as addiction, which involves compulsive use despite harm. A planned, gradual taper with your prescriber lets the cell reset at a comfortable pace.
Opioid-induced hyperalgesia
Occasionally, longer opioid use makes the nervous system more sensitive to pain rather than less. This is called opioid-induced hyperalgesia. It is separate from tolerance and less common. Tolerance means the drug works less well on the same pain; hyperalgesia means pain itself spreads or intensifies, sometimes to areas that were not painful before. Only a clinician can tell these apart, so report pain that is spreading or changing. If you have stopped and are wondering about lingering discomfort, see what to expect if pain returns after stopping oxycodone.
Can we separate relief from risk? The biased-agonist idea
Remember the two partners a switched-on mu receptor can call: the G protein and beta-arrestin. Early laboratory work in mice suggested an appealing split. The G protein route seemed to carry most of the pain relief, while the beta-arrestin route seemed linked to slowed breathing, constipation and tolerance. If that held up, a drug that leaned toward the G protein pathway, a so-called biased agonist, might give relief with fewer dangers.
That idea led to oliceridine (brand name Olinvyk). The FDA approved it in August 2020 for intravenous use only, in hospitals and other controlled clinical settings, for severe acute pain. It is not a tablet and is not used at home. Importantly, the agency noted that its side-effect profile, including breathing risk, was similar to other opioids. You can read the FDA announcement on oliceridine for the official summary.
Since then, the clean split has looked messier. Later studies suggested breathing effects may run partly through G protein signalling itself. The science is still evolving. For patients, the takeaway is simple: no current opioid has separated pain relief from breathing risk, so the usual precautions apply to every one of them.
Receptor genes and why responses differ
The instructions for building the mu receptor sit in a gene called OPRM1. Like most genes, it comes in slightly different versions. The best-studied one is known as A118G, a single-letter change that swaps one building block near the outer end of the receptor. Some studies linked the G version to needing more opioid after surgery; others found little or no difference.
Because the findings are inconsistent, the Clinical Pharmacogenetics Implementation Consortium concluded in its 2021 guideline that evidence for OPRM1 (and for the related COMT gene) is too limited to guide opioid prescribing. It gives genotype advice for codeine and tramadol, but not oxycodone. You can find the CPIC opioid guideline abstract on PubMed. That difference with codeine and tramadol also shapes how they compare in practice; see oxycodone versus tramadol for more.
Genes are only one thread. Other medicines, pain type and even expectations also shape how a medicine feels. Our deeper look at genetics and oxycodone response explains what testing can and cannot tell you today.
Reader Q&A
Q: Do all opioids hit the same receptors?
A: Most prescription pain opioids, including oxycodone, morphine, hydromorphone, and fentanyl, act mainly at the mu receptor, though some touch delta or kappa receptors a little too. They differ in how tightly they bind, how strongly they switch the receptor on, how fast they reach the brain and how long they last. Switching from one opioid to another should always be planned by a prescriber.
Q: Why does naloxone wear off before some opioids?
A: Naloxone is cleared from the body faster than many opioids, particularly extended-release tablets, methadone and some potent illicit synthetic drugs. Once naloxone levels drop, opioid still circulating in the blood can bind the receptors again and slow breathing for a second time. Anyone given naloxone needs emergency care and someone watching them, even if they seem fully awake.
Q: Can receptors “reset” after stopping?
A: Largely, yes. After a medicine is stopped, receptors return to the surface and the cell’s internal machinery settles back down. Acute withdrawal usually passes within days to a couple of weeks; sleep and mood can take longer. Because tolerance fades, taking a previous dose after a break can be dangerous, so always check with your prescriber before restarting.
Q: Why do I itch on oxycodone?
A: Mu receptors in the spinal cord and brain help regulate itch signals, and switching them on can turn itch sensations up, often around the face, nose and upper body. Some opioids also trigger histamine release from cells in the skin, though oxycodone does this less than morphine. Itching alone is usually not dangerous, but hives, swelling of the lips or tongue, or trouble breathing need emergency help right away.
Q: Are kratom and loperamide related to opioid receptors?
A: Yes, both act at the mu receptor. Loperamide, a common diarrhoea medicine, is a mu agonist that mostly stays in the gut at labelled doses; taken in very large amounts, it has caused serious heart rhythm problems. Kratom is a plant product whose main compounds act at opioid receptors, and it is not FDA-approved for any medical use. Tell your care team if you use either one.
Q: Does exercise really release endorphins?
A: Sustained, fairly hard exercise does seem to raise beta-endorphin levels, and studies using naloxone suggest the body’s own opioids contribute to post-exercise pain relief. The “runner’s high” probably involves other systems too. Ask your care team which activities suit you.